[A16-70] Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

Last updated 17.09.2019

Project no.:
A16-70

Commission:
Commission awarded on 24.11.2016 by the Federal Joint Committee (G-BA).

Report type:
Report

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Muscles, bones and joints

17.09.2019

Only few differences between biologics detectable / Operationalization of outcomes can influence results

Press release

Extract of the final report: Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

EN, PDF, 1 MB, PDF

published on Sep 17, 2019
Final report: Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

DE, PDF, 14 MB, PDF

published on Sep 17, 2019
Documentation of comments on the preliminary report: Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

DE, PDF, 6 MB, PDF

published on Sep 17, 2019
Preliminary report: Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

DE, PDF, 12 MB, PDF

published on Jun 6, 2018
Report plan version 1.0: Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

DE, PDF, 297 kB, PDF

published on Jul 6, 2017
Documentation and evaluation of comments on the preliminary report plan: Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

DE, PDF, 5 MB, PDF

published on Jul 6, 2017
Preliminary report plan: Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

DE, PDF, 215 kB, PDF

published on Mar 1, 2017

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.